Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 5/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | STAT3 | P40763 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.31 |
| ▸ | SELE | P16581 | 2/20 | 0.31 |
| ▸ | VCAM1 | P19320 | 2/20 | 0.31 |
| ▸ | MMP1 | P03956 | 3/20 | 0.31 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7862190 | 0.88 | S1PR5 (0.37) | MMP13MMP2MMP1P2RX3NPY5R | |
| SCHEMBL6695546 | 0.82 | P2RX3 (0.38) | MMP13P2RX3 | |
| SCHEMBL6693902 | 0.75 | ACACB (0.34) | ACACBMMP13CYP3A4HTTMAPK14 | |
| SCHEMBL6691337 | 0.65 | HSD17B10 (0.35) | HTT | |
| SCHEMBL6694306 | 0.64 | S1PR5 (0.36) | MMP2ICAM1SELEVCAM1P2RX3 | |
| SCHEMBL6689084 | 0.64 | CYP17A1 (0.36) | MMP13 | |
| SCHEMBL6693849 | 0.63 | S1PR5 (0.44) | MMP13LMNAMMP2MMP1 | |
| SCHEMBL6693872 | 0.62 | MMP1 (0.42) | ACACBMMP13MMP2MMP1P2RX3 | |
| SCHEMBL16866564 | 0.61 | SRD5A2 (0.60) | MMP13CYP3A4HTTMAPK14SMN1; SMN2 | |
| SCHEMBL6694975 | 0.60 | MMP2 (0.46) | MMP13HTTSMN1; SMN2LMNAMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1134215-B1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases | PFIZER PROD INC (US) | 2004-10-06 | — | — | EP | claimed |
| US-20020147224-A1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases | ROBINSON RALPH P (US) | 2002-10-10 | — | — | US | claimed |
| US-20010041710-A1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases | PFIZER PRODUCTS INC. | 2001-11-15 | — | — | US | claimed |
| EP-1134215-A1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases | Pfizer Products Inc. (US) | 2001-09-19 | — | — | EP | claimed |
| EP-1134215-B1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases | PFIZER PROD INC (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20020147224-A1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases | ROBINSON RALPH P (US) | 2002-10-10 | — | — | US | disclosed |
| US-6458822-B2 | (4R)-1-(4-(4-FLUOROPHENOXY)BENZYL)-2-OXO-IMIDAZOLIDINE-4 -CARBOXYLIC ACID HYDROXYAMIDE, FOR EXAMPLE; TREATING VARIOUS DISEASES INCLUDING OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, CANCER, OSTEOPOROSIS, STROKES | PFIZER INC. | 2002-10-01 | — | — | US | disclosed |
| US-20010041710-A1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases | PFIZER PRODUCTS INC. | 2001-11-15 | — | — | US | disclosed |
| EP-1134215-A1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases | Pfizer Products Inc. (US) | 2001-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147224-A1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases | MMP1, MMP8, MMP13 | ACACB 2373/4885MMP13 3/4885CYP3A4 819/4885 |
| US-20010041710-A1 | 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases | MMP1, MMP8, MMP13 | ACACB 2373/4885MMP13 3/4885CYP3A4 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.